Epidemics

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations…

2 years ago

PillSafe Provides a Solution to the Opioid Epidemic’s $1 Trillion-Plus Impact on the US Economy

As federal and state governments implement far-ranging programs to address the crisis, PillSafe offers a technology-based solution that ensures patients…

2 years ago

Owlet Announces UK Medical Certification of Dream Sock®

Parents in the United Kingdom will soon have access to Owlet’s Dream Sock with UKCA certificationLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”…

2 years ago

Owlet Announces UK Medical Certification of Dream Sock®

Parents in the United Kingdom will soon have access to Owlet’s Dream Sock with UKCA certificationLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”…

2 years ago

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an…

2 years ago

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4…

2 years ago

Owlet Announces European Medical Certification of Dream SockⓇ

Parents will soon have access to Owlet’s Dream Sock with medically-certified CE-Marking across the European marketsLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”…

2 years ago

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab…

2 years ago

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in…

2 years ago